Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 159

1.

Elevated plasma high-mobility group box 1 protein is a potential marker for neuromyelitis optica.

Wang KC, Tsai CP, Lee CL, Chen SY, Chin LT, Chen SJ.

Neuroscience. 2012 Dec 13;226:510-6. doi: 10.1016/j.neuroscience.2012.08.041.

PMID:
23122444
2.

CSF high-mobility group box 1 is associated with intrathecal inflammation and astrocytic damage in neuromyelitis optica.

Uzawa A, Mori M, Masuda S, Muto M, Kuwabara S.

J Neurol Neurosurg Psychiatry. 2013 May;84(5):517-22. doi: 10.1136/jnnp-2012-304039. Epub 2012 Dec 19.

PMID:
23255728
3.

Cerebrospinal fluid high-mobility group box protein 1 in neuromyelitis optica and multiple sclerosis.

Wang H, Wang K, Wang C, Xu F, Zhong X, Qiu W, Hu X.

Neuroimmunomodulation. 2013;20(2):113-8. doi: 10.1159/000345994. Epub 2013 Jan 10.

PMID:
23328212
4.

Quantitative measurement of anti-aquaporin-4 antibodies by enzyme-linked immunosorbent assay using purified recombinant human aquaporin-4.

Kim W, Lee JE, Li XF, Kim SH, Han BG, Lee BI, Kim JK, Choi K, Kim HJ.

Mult Scler. 2012 May;18(5):578-86. doi: 10.1177/1352458511424590. Epub 2011 Sep 30.

PMID:
21965418
5.

Increased plasma levels of pentraxin 3 in patients with multiple sclerosis and neuromyelitis optica.

Wang H, Wang K, Wang C, Zhong X, Qiu W, Hu X.

Mult Scler. 2013 Jun;19(7):926-31. doi: 10.1177/1352458512457845. Epub 2012 Sep 25.

PMID:
23012252
6.

Plasma osteopontin levels are associated with disease activity in the patients with multiple sclerosis and neuromyelitis optica.

Shimizu Y, Ota K, Ikeguchi R, Kubo S, Kabasawa C, Uchiyama S.

J Neuroimmunol. 2013 Oct 15;263(1-2):148-51. doi: 10.1016/j.jneuroim.2013.07.005. Epub 2013 Jul 30.

PMID:
23910387
7.
8.

Increased plasma interleukin-32 expression in patients with neuromyelitis optica.

Wang H, Wang K, Wang C, Xu F, Qiu W, Hu X.

J Clin Immunol. 2013 Apr;33(3):666-70. doi: 10.1007/s10875-012-9837-2. Epub 2012 Nov 21.

PMID:
23180362
9.

Elevated plasma level of HMGB1 is associated with disease activity and combined alterations with IFN-α and TNF-α in systemic lupus erythematosus.

Ma CY, Jiao YL, Zhang J, Yang QR, Zhang ZF, Shen YJ, Chen ZJ, Zhao YR.

Rheumatol Int. 2012 Feb;32(2):395-402. doi: 10.1007/s00296-010-1636-6. Epub 2010 Dec 1.

PMID:
21120500
10.

Increased plasma levels of epithelial neutrophil-activating peptide 78/CXCL5 during the remission of Neuromyelitis optica.

Yang T, Wang S, Zheng Q, Wang L, Li Q, Wei M, Du Z, Fan Y.

BMC Neurol. 2016 Jul 11;16:96. doi: 10.1186/s12883-016-0622-3.

11.

Characteristic cerebrospinal fluid cytokine/chemokine profiles in neuromyelitis optica, relapsing remitting or primary progressive multiple sclerosis.

Matsushita T, Tateishi T, Isobe N, Yonekawa T, Yamasaki R, Matsuse D, Murai H, Kira J.

PLoS One. 2013 Apr 18;8(4):e61835. doi: 10.1371/journal.pone.0061835. Print 2013.

12.

Revised diagnostic criteria for neuromyelitis optica (NMO). Application in a series of suspected patients.

Saiz A, Zuliani L, Blanco Y, Tavolato B, Giometto B, Graus F; Spanish-Italian NMO Study Group.

J Neurol. 2007 Sep;254(9):1233-7. Epub 2007 Apr 2.

PMID:
17401734
13.

Distinct serum cytokine profiles in neuromyelitis optica and multiple sclerosis.

Wang KC, Lee CL, Chen SY, Chen JC, Yang CW, Chen SJ, Tsai CP.

J Interferon Cytokine Res. 2013 Feb;33(2):58-64. doi: 10.1089/jir.2012.0040.

PMID:
23398365
14.

Plasma sCD28, sCTLA-4 levels in neuromyelitis optica and multiple sclerosis during relapse.

Wang H, Wang K, Zhong X, Dai Y, Wu A, Li Y, Hu X.

J Neuroimmunol. 2012 Feb 29;243(1-2):52-5. doi: 10.1016/j.jneuroim.2011.11.010. Epub 2011 Dec 15.

PMID:
22177277
15.

Interferon alpha association with neuromyelitis optica.

Asgari N, Voss A, Steenstrup T, Kyvik KO, Stenager E, Lillevang ST.

Clin Dev Immunol. 2013;2013:713519. doi: 10.1155/2013/713519. Epub 2013 Nov 18.

16.

Poor responses to interferon-beta treatment in patients with neuromyelitis optica and multiple sclerosis with long spinal cord lesions.

Wang KC, Lin KH, Lee TC, Lee CL, Chen SY, Chen SJ, Chin LT, Tsai CP.

PLoS One. 2014 Jun 2;9(6):e98192. doi: 10.1371/journal.pone.0098192. eCollection 2014.

17.

Elevated C-X-C motif ligand 13 and B-cell-activating factor levels in neuromyelitis optica during remission.

Wang S, Yang T, Wan J, Zhang Y, Fan Y.

Brain Behav. 2017 Mar 10;7(4):e00648. doi: 10.1002/brb3.648. eCollection 2017 Apr.

18.

Astrocytic damage is far more severe than demyelination in NMO: a clinical CSF biomarker study.

Takano R, Misu T, Takahashi T, Sato S, Fujihara K, Itoyama Y.

Neurology. 2010 Jul 20;75(3):208-16. doi: 10.1212/WNL.0b013e3181e2414b.

PMID:
20644148
19.

[Neuromyelitis optica and anti-aquaporin 4 antibody--distinct from multiple sclerosis].

Misu T, Takahashi T, Nakashima I, Fujihara K, Itoyama Y.

Rinsho Byori. 2009 Mar;57(3):262-70. Review. Japanese.

PMID:
19363997
20.

Preferential increase of B-cell activating factor in the cerebrospinal fluid of neuromyelitis optica in a white population.

Vaknin-Dembinsky A, Brill L, Orpaz N, Abramsky O, Karussis D.

Mult Scler. 2010 Dec;16(12):1453-7. doi: 10.1177/1352458510380416. Epub 2010 Oct 8.

PMID:
20935029

Supplemental Content

Support Center